3.40Open3.40Pre Close0 Volume2 Open Interest15.00Strike Price0.00Turnover0.00%IV3.81%PremiumDec 20, 2024Expiry Date2.94Intrinsic Value100Multiplier4DDays to Expiry0.46Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma4.39Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Stoke Therapeutics Stock Discussion
Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome
In the rapidly evolving world of biotechnology, companies like Stoke Therapeutics are pioneering groundbreaking treatments that could potentially change the lives of patients with severe diseases. The recent buzz surrounding Stoke Therapeutics, particularly their work on an anti-epilepsy drug, STK-001, underscores the transformative potential of RNA-based therapies in addres...
No comment yet